entertainment -WSS

entertainment

author：knowledge 2025-09-28 01:36:13 - browse：1

Christopher Boerner -- biotech JPM coverage from STAT — Bristol CEO Christopher Boerner Business Wire via AP

SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two months. But in trying to sell the company to investors on Monday at the annual J.P. Morgan Healthcare Conference, he pointed to the company’s 150-year history.

He spoke of the “next chapter” for BMS, which saw its stock fall 27% last year, and said that the company would be going through a “period of renewal.” Basically, the tide comes in, but it also goes out. Patents on big-selling medicines expire, but new medicines will come to take their place.

Investors may not be able to view those changes with equanimity. Sales of Bristol’s top sellers will decline significantly or vanish as generic or biosimilar medicines emerge. That includes Eliquis, the blood thinner for stroke prevention that will be one of the first medications subject to price negotiation under the Inflation Reduction Act; Revlimid, the best-selling multiple myeloma medicine that Bristol acquired when it bought Celgene for $74 billion in 2019; and Opdivo, Bristol’s pioneering cancer immunotherapy, which is an $8 billion seller.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Medicare coverage of Wegovy, once blocked, now looks possible

focus

WSS

How many hemophilia patients actually want gene therapy?

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Extreme heat events are a public health emergency

FDA advisers back CAR

Sanofi CEO defends move to abandon profit guidance, boost research

Wikipedia

entertainment

Wikipedia

Bright Health sells Medicare Advantage business to Molina

Ambulance rides for just $100? Advisers want major billing fixes

23andMe had bad news about my health. I wish a person had delivered it

Senate panel clears PBM, hopsital reforms

The cancer drug shortage isn’t new — and neither are the solutions

Why scientists need input from humanists on sensitive research

Guidelines to prevent youth baseball injuries need more muscle

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Moonlake's readout produced a cash windfall. Risks remain

John Green on his newest strategy for fighting tuberculosis

knowledge

EPA limits use of carcinogenic gas for sterilizing medical devices

Pushing for an NIH office for post

Steward Health Care Massachusetts hospitals face fiscal disaster

More doctors should go into startup world

How to save health care price transparency rules

Amid AI frenzy, a top HHS official's quest to create safeguards

focus

focus

leisure time

Wikipedia